Markets›Health care›ABT

Abbott Laboratories

ABT
101.29
+0.22 (+0.22%)
Closing price for Sep 25, 2026 from Polygon.io
Income statement Balance sheet Cash flow | Annual Quarterly |Download CSV
Income statement (USD) Q1 2026
ended Mar 31, 2026
Q4 2025
ended Dec 31, 2025
Q3 2025
ended Sep 30, 2025
Q2 2025
ended Jun 30, 2025
Q1 2025
ended Mar 31, 2025
Q4 2024
ended Dec 31, 2024
Q3 2024
ended Sep 30, 2024
Q2 2024
ended Jun 30, 2024
Revenue 11.16B11.46B11.37B11.14B10.36B10.97B10.63B10.38B
Cost of revenue 4.89B4.92B5.08B4.85B4.47B4.94B4.70B4.60B
Gross profit 6.27B6.54B6.29B6.29B5.89B6.03B5.94B5.77B
Research and development 767.00M735.00M766.00M725.00M716.00M749.00M713.00M698.00M
Selling, general and admin 3.74B3.13B3.05B3.09B3.06B2.91B2.90B2.94B
Operating expenses 9.82B9.21B9.31B9.09B8.66B9.06B8.78B8.71B
Operating income 1.34B2.25B2.06B2.05B1.69B1.91B1.86B1.67B
EBITDA 1.73B2.62B2.43B2.41B2.03B2.25B2.19B2.00B
Interest expense 174.00M120.00M121.00M121.00M131.00M136.00M142.00M140.00M
Income before tax 1.45B2.36B2.18B2.15B1.78B2.03B1.94B1.61B
Income tax 372.00M582.00M536.00M371.00M453.00M-7.20B294.00M305.00M
Net income 1.08B1.78B1.64B1.78B1.32B9.23B1.65B1.30B
EPS 0.621.010.941.020.765.280.940.74
EPS (diluted) 0.611.020.941.010.765.260.940.74
Diluted shares 1.75B-1.16M1.75B1.75B1.75B-1.43M1.75B1.75B
Dividends per share 0.630.630.590.590.590.590.550.55

From Abbott Laboratories's 10-K and 10-Q filings with the SEC. Fourth quarters, and quarters where the company only reported year-to-date totals, are worked out by subtracting the earlier quarters. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read income statement or reading a 10-K.

Charts

Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.